MARKET

ATRA

ATRA

Atara Biotherape
NASDAQ
8.18
+0.31
+3.94%
Closed 19:30 11/09 EST
OPEN
7.87
PREV CLOSE
7.87
HIGH
8.31
LOW
7.69
VOLUME
13.70K
TURNOVER
0
52 WEEK HIGH
19.15
52 WEEK LOW
3.920
MARKET CAP
82.11M
P/E (TTM)
-6.9129
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATRA last week (1102-1106)?
Weekly Report · 1d ago
Weekly Report: what happened at ATRA last week (1026-1030)?
Weekly Report · 11/02 10:07
Weekly Report: what happened at ATRA last week (1019-1023)?
Weekly Report · 10/26 10:07
Atara Biotherapeutics Defendants Move to Dismiss Amended Securities Class Action Over Tab-cel FDA Rejection
TipRanks · 10/23 09:25
Weekly Report: what happened at ATRA last week (1012-1016)?
Weekly Report · 10/19 10:07
Canaccord Genuity Keeps Their Buy Rating on Atara Biotherapeutics (ATRA)
TipRanks · 10/15 11:37
Atara partner receives acceptance by FDA of BLA resubmission for tabelecleucel
TipRanks · 10/14 12:20
Atara Biotherapeutics' Partner Pierre Fabre Pharmaceuticals Receives FDA Acceptance To Refile Biologics License Application For Tabelecleucel To Treat Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Benzinga · 10/14 12:08
More
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

Webull offers Atara Biotherapeutics Inc stock information, including NASDAQ: ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.